Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase

Patent metadata

Field	Value
Publication number	US-10064853-B2
Application number	US-201715632809-A
Country	US
Kind code	B2
Filing date	Jun 26, 2017
Priority date	Jun 21, 2013
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I)

First claim

The invention claimed is:

1. A method for treating acute myocardial infarction, transient ischemic attacks, peripheral vascular disease, pulmonary embolism, or deep vein thrombosis in a patient, comprising administering to the patient a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or solvent, wherein:
R 1 is OH or acyloxy;
R 2 is selected from H, lower alkyl, and halogen;
R 3 and R 4 are independently selected from H, F, and alkyl, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group or a substituted or unsubstituted 3-7 membered cycloalkyl ring;
R 5 is OR 7 , or NR 7 R 8 , wherein R 7 and R 8 are each independently selected from H and substituted or unsubstituted alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, or taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-7 membered heterocyclyl ring;
W represents a C 1 -C 3 alkylene group;
X is selected from O, S, and NR 9 , wherein R 9 is H or lower alkyl; and
R 6 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

2. The method according to claim 1 , wherein R 1 is OH.

3. The method according to claim 1 , wherein R 2 is H or Cl.

4. The method according to claim 1 , wherein R 3 and R 4 are H, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group.

5. The method according to claim 1 , wherein R 5 is OR 7 , wherein R 7 is substituted or unsubstituted alkyl.

6. The method according to claim 1 , wherein W is ethylene.

7. The method according to claim 1 , wherein X is O.

8. The method according to claim 1 , wherein R 6 is substituted or unsubstituted aryl.

9. The method according to claim 1 , wherein the compound is a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

10. A method for inhibiting protein disulfide isomerase in a cell, comprising contacting the cell with a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or solvent, wherein:
R 1 is OH or acyloxy;
R 2 is selected from H, lower alkyl, and halogen;
R 3 and R 4 are independently selected from H, F, and alkyl, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group or a substituted or unsubstituted 3-7 membered cycloalkyl ring;
R 5 is OR 7 , or NR 7 R 8 , wherein R 7 and R 8 are each independently selected from H and substituted or unsubstituted alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, or taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-7 membered heterocyclyl ring;
W represents a C 1 -C 3 alkylene group;
X is selected from O, S, and NR 9 , wherein R 9 is selected from H or lower alkyl; and
R 6 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

11. The method according to claim 10 , wherein R 1 is OH.

12. The method according to claim 10 , wherein R 2 is H or Cl.

13. The method according to claim 10 , wherein R 3 and R 4 are H, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group.

14. The method according to claim 10 , wherein R 5 is OR 7 , wherein R 7 is substituted or unsubstituted alkyl.

15. The method according to claim 10 , wherein W is ethylene.

16. The method according to claim 10 , wherein X is O.

17. The method according to claim 10 , wherein R 6 is substituted or unsubstituted aryl.

18. The method according to claim 10 , wherein the compound is a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

Assignees

• Beth Israel Deaconess Medical Ct Inc
• Broad Inst Inc

Inventors

• Flaumenhaft Robert
• Nag Partha Pratim
• Pilyugina Tatiana
• Pu Jun
• Dandapani Sivaraman
• Munoz Benito
• Dockendorff Chris

Classifications

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07D211/62

  attached in position 4 · CPC title